Type
- ARTG (491)
- Cancellation by sponsor (465)
- Australian Public Assessment Report (AusPAR) (63)
- Prescription medicine registration (40)
- Section 14, TGO91 consent (21)
- Prescription medicine decision summary (19)
- Designation or determination (9)
- Cancellation or suspension (7)
- Prescription medicine evaluation (2)
Date
- 2024 (52)
- 2023 (73)
- 2022 (61)
- 2021 (126)
- 2020 (107)
- 2019 (98)
- 2018 (98)
- 2017 (74)
- 2016 (12)
- 2015 (22)
- 2014 (23)
- 2013 (9)
- 2012 (9)
- 2011 (14)
- 2010 (29)
- 2009 (15)
- 2008 (6)
- 2007 (12)
- 2006 (9)
- 2005 (4)
- 2004 (8)
- 2003 (9)
- 2002 (13)
- 2001 (8)
- 2000 (22)
- 1999 (12)
- 1998 (12)
- 1997 (18)
- 1996 (10)
- 1995 (3)
- 1994 (33)
- 1993 (19)
- 1992 (8)
- 1991 (89)
Results for
"[search-keyword]"
Sponsor content
1117 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for IXIFI infliximab 100 mg powder for injection vial.
-
Australian Public Assessment Report (AusPAR)COMIRNATY Original/Omicron BA.4-5 Vaccine has been provisionally approved for immunisation against coronavirus disease 2019 (COVID-19) caused by SARSCoV-2 in individuals 6 months of age or older.
-
Australian Public Assessment Report (AusPAR)Velsipity (Etrasimod) has been approved for the treatment of adults with moderately to severely active ulcerative colitis who have not benefited from prior therapies
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TALZENNA talazoparib (as tosilate) 0.1 mg capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TALZENNA talazoparib (as tosilate) 0.5 mg capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TALZENNA talazoparib (as tosilate) 0.35 mg capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for COMIRNATY Omicron XBB.1.5 (raxtozinameran) COVID-19 VACCINE 30 micrograms/0.3 mL suspension for injection prefilled plastic syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for COMIRNATY Omicron XBB.1.5 (raxtozinameran) COVID-19 VACCINE 30 micrograms/0.3 mL suspension for injection prefilled glass syringe.
-
Australian Public Assessment Report (AusPAR)Xeljanz (tofacitinib) has been approved for the treatment of ankylosing spondylitis and for active polyarticular course juvenile idiopathic arthritis.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LITFULO ritlecitinib (as tosylate) 50 mg hard capsule bottle.